Coherus Oncology (CHRS) Proxy filing summary

Executive summary

• Annual Meeting convened on May 27, 2026, with a quorum present to address several proposals.

• Voting completed on Proposals 1, 2, 3, and 5; Proposal 4 required adjournment for further vote counting.

• Meeting adjourned and scheduled to reconvene on May 29, 2026, specifically to finalize voting on Proposal 4.

Voting matters and shareholder proposals

• Proposal 4 concerns reducing the exercise price of certain outstanding stock options.

• Approval of Proposal 4 requires a majority of shares cast, excluding abstentions and broker non-votes.

• If approved, eligible options will be repriced to the closing trading price on May 29, 2026, and their term extended by 10 years.

• Early termination or exercise before May 29, 2027, will revert the exercise price to the original amount.

Board of directors and corporate governance

• The board or compensation committee retains discretion to determine exceptions regarding option repricing.